EnGen Bio LLC, based in Redwood City, CA, is a pioneering biotech company focused on developing a therapy and vaccine to provide lifetime immunity to Type A flu. Their innovative approach targets a novel epitope on the flu virus's M1 matrix protein, aiming to elicit long-lasting and broadly neutralizing antibody responses in both humans and animals.
Recognizing the global threat posed by the next flu pandemic, EnGen Bio has garnered support from prestigious organizations such as the National Institutes of Health, Department of Defense, Department of Agriculture, and the Bill and Melinda Gates Foundation. With seven patents protecting their valuable discoveries, the company aims to accelerate their early stage vaccine development program to address the $8 billion potential market, including the human, veterinary, and flu treatment antibody sectors.
Generated from the website